Yes, Rinvoq (upadacitinib) increases lipid levels
Upadacitinib causes dose-related increases in total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides, with lipid elevations typically peaking by Week 8-12 and remaining stable thereafter. This is a well-established effect documented in FDA labeling and multiple clinical guidelines 1, 2, 3.
Lipid Changes with Upadacitinib
Magnitude of Lipid Increases
Based on controlled trials up to 12-14 weeks, the following mean increases occur with standard dosing 1:
- LDL cholesterol: increases by approximately 15-17 mg/dL
- HDL cholesterol: increases by approximately 8-9 mg/dL
- Triglycerides: increases by approximately 13-14 mg/dL
- LDL/HDL ratio: remains stable despite individual component increases
A meta-analysis confirmed these findings, showing upadacitinib 15 mg increased LDL-C by 15.18 mg/dL (95% CI: 7.77-22.59) and HDL-C by 7.89 mg/dL (95% CI: 7.08-8.69) 4.
Time Course
Lipid elevations follow a predictable pattern:
- Peak increases occur by Week 8-12 after initiation 1, 3
- Levels remain stable after the initial peak
- The effect persists throughout treatment duration
Clinical Management
Monitoring Requirements
Check lipid parameters at baseline, then at 4-12 weeks after initiation (depending on indication), and annually thereafter 2, 3. The 2024 ACR/CHEST guidelines specify monitoring at baseline, 4-8 weeks after starting, then annually for JAK inhibitors 2. The 2024 AAD atopic dermatitis guidelines recommend checking lipids at 4 weeks for abrocitinib and 12 weeks for upadacitinib 3.
Treatment of Elevated Lipids
Statins are effective at reducing lipid levels in patients on upadacitinib who develop sustained elevations 5. The FDA label notes that "elevations in LDL cholesterol decreased to pre-treatment levels in response to statin therapy" 1. Manage patients according to standard clinical guidelines for hyperlipidemia based on their cardiovascular risk profile.
Cardiovascular Risk Implications
Important Context
While upadacitinib increases lipid parameters, the clinical significance for cardiovascular outcomes remains uncertain:
- The FDA label explicitly states: "The effect of these lipid parameter elevations on cardiovascular morbidity and mortality has not been determined" 1
- A meta-analysis of 15 placebo-controlled trials (n=7,695) found no significant effect on major adverse cardiovascular events (MACE) during follow-up ≤52 weeks (RR: 0.62; 95% CI: 0.24-1.60) 4
- Real-world data from IBD patients showed cholesterol increases without changes in the LDL/HDL ratio 6
JAK Inhibitor Class Warnings
The FDA has applied class-wide warnings for JAK inhibitors based on data from tofacitinib in rheumatoid arthritis patients ≥50 years with cardiovascular risk factors 3, 1. However, this population differs substantially from most patients initiating treatment for other indications, and upadacitinib is a more selective JAK-1 inhibitor than tofacitinib.
Key Caveats
- Dose-dependent effect: Higher doses (30 mg) produce slightly greater lipid increases than standard doses (15 mg) 1
- Both "good" and "bad" cholesterol increase: The parallel rise in HDL cholesterol may partially offset cardiovascular risk from LDL increases
- Individual variation: Not all patients experience clinically significant lipid elevations
- Statin responsiveness: Lipid elevations respond well to standard statin therapy when treatment is indicated 1, 5
Monitor lipid parameters regularly and treat elevated lipids according to standard cardiovascular risk assessment guidelines, recognizing that the lipid changes are expected and manageable with statins when necessary.